Therapeutic Antibodies Methods and Protocols / [electronic resource] :
edited by Antony S. Dimitrov.
- XVIII, 585 p. online resource.
- Methods in Molecular Biology™, Methods and Protocols, 525 1064-3745 ; .
- Methods in Molecular Biology™, Methods and Protocols, 525 .
Recombinant Antigens -- Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon? -- Preparation of Recombinant Viral Glycoproteins for Novel and Therapeutic Antibody Discovery -- Antibody Libraries -- Design of a Human Synthetic Combinatorial Library of Single-Chain Antibodies -- Construction of a Human Antibody Domain (VH) Library -- Generation and Selection of Rabbit Antibody Libraries by Phage Display -- Construction of a Large Naïve Human Phage-Displayed Fab Library Through One-Step Cloning -- Antibody Discovery -- Identification of Target and Function Specific Antibodies for Effective Drug Delivery -- Screening of Specific Internalization Fab Fragment from Human Naive Phage Library by Combinational Bio-Panning -- Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41 -- Selection of Non-aggregating VH Binders from Synthetic VH Phage-Display Libraries -- Isolation of Full-Length IgG Antibodies from Combinatorial Libraries Expressed in Escherichia coli -- Multiplexed Flow Cytometry: High-Throughput Screening of Single-Chain Antibodies -- Human Antibody Repertoires -- Rapid Screening Platform for Stabilization of scFvs in Escherichia coli -- Antibody Engineering -- In Vitro Antibody Affinity Maturation Targeting Germline Hotspots -- Affinity Maturation by Phage Display -- Production of Chimeric Heavy-Chain Antibodies -- Mammalian Cell Display for Antibody Engineering -- Improving Antibody Binding Affinity and Specificity for Therapeutic Development -- Construction and Production of an IgG-Like Tetravalent Bispecific Antibody for Enhanced Therapeutic Efficacy -- Deimmunization of Monoclonal Antibodies -- Anti-CD22 Onconase: Preparation and Characterization -- Antibody–Cytotoxic Agent Conjugates: Preparation and Characterization -- Antibody Preclinical Development -- High-Level Production of a Humanized ImmunoRNase Fusion Protein from Stably Transfected Myeloma Cells -- Antibody Fragment Expression and Purification -- Scaling-Up and Production of Therapeutic Antibodies for Preclinical Studies -- Antibody Production by the Gram-Positive Bacterium Bacillus megaterium -- Neutralization of HIV by Antibodies -- Dynamics of Antibody Domains Studied by Solution NMR -- In Vivo Method for Establishing Synergy Between Antibodies to Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 -- Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches -- Antibody Sequence Analysis -- Organizing, Exploring, and Analyzing Antibody Sequence Data: The Case for Relational-Database Managers.
With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes highlighting tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Therapeutic Antibodies: Methods and Protocols serves as a key resource for researchers and antibody engineers investigating and participating in this rapidly growing therapeutic market segment.